Companies BioXcel Therapeutics
BioXcel Therapeutics (BTAI): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me BioXcel Therapeutics’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $4,731,147FY2023
- $1,119,245FY2024
CEO total pay was $1,119,245 in fiscal 2024, down from $4,731,147 in fiscal 2023.
FY2024: salary $1,001,570 · bonus $0 · stock awards $0 · option awards $101,250
Frequently asked questions
Who was the highest-paid executive at BioXcel Therapeutics in fiscal 2024?
As disclosed, Vimal Mehta (Chief Executive Officer) was the highest-paid executive at BioXcel Therapeutics in fiscal 2024, with total compensation of $1,119,245.
How did shareholders vote on BioXcel Therapeutics's executive compensation?
As disclosed, 80.37% of shareholders supported BioXcel Therapeutics's executive compensation in the latest say-on-pay vote.
How much does BioXcel Therapeutics spend in total on board compensation for fiscal 2024?
As disclosed, BioXcel Therapeutics reported total board compensation of $643,119 for fiscal 2024.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Vimal Mehta | $1,001,570 | $0 | $0 | $101,250 | $0 | $0 | $16,425 | $1,119,245 |
| Chief Executive Officer | ||||||||
| Javier Rodriguez | 423,833 | 0 | 181,755 | 398,530 | 0 | 0 | 8,625 | 1,012,552 |
| Senior VP and Chief Legal Officer | ||||||||
| Richard Steinhart | 409,872 | 0 | 181,755 | 398,339 | 0 | 0 | 4,128 | 998,216 |
| SVP and Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Vimal Mehta | $1,119,245 | $4,731,147 | — | ↓ −3,611,902 |
| Javier Rodriguez | 1,012,552 | 1,121,943 | — | ↓ −109,391 |
| Richard Steinhart | 998,216 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company provides base salaries to reflect skill set, experience, role, and responsibilities, and offers discretionary annual cash bonuses based on company and individual performance goals. Long-term incentives are provided through stock options, time-based restricted stock units, and performance-based restricted stock units to align executive interests with strategic clinical and operational objectives.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford, a part of Aon plc |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2024
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Vimal Mehta | OPTION | 2024-07-22 | — | — | 6,250 | — | $101,250 |
| Vimal Mehta | PSU | 2024-07-22 | — | 15,625 | — | — | — |
| Javier Rodriguez | PSU | 2024-07-22 | — | 4,375 | — | — | — |
| Javier Rodriguez | RSU | 2024-07-22 | — | — | 625 | — | 181,755 |
| Richard Steinhart | PSU | 2024-07-22 | — | 4,375 | — | — | — |
| Richard Steinhart | OPTION | 2024-07-22 | — | — | 1,875 | — | 398,339 |
| Richard Steinhart | RSU | 2024-07-22 | — | — | 625 | — | 181,755 |
| Javier Rodriguez | OPTION | 2024-07-22 | — | — | 1,875 | — | 398,530 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Vimal Mehta | $0 | $0 | $101,250 | 0.0% |
| Javier Rodriguez | 181,755 | 0 | 398,530 | 0.0% |
| Richard Steinhart | 181,755 | 0 | 398,339 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Richard Steinhart | Option | 79 | 658.72 | — |
| Javier Rodriguez | Option | 84 | 878.4 | — |
| Javier Rodriguez | Option | 103 | 381.44 | — |
| Javier Rodriguez | RSU | 163 | — | 975 |
| Richard Steinhart | RSU | 163 | — | 975 |
| Javier Rodriguez | RSU | 317 | — | 1,896 |
| Richard Steinhart | RSU | 317 | — | 1,896 |
| Javier Rodriguez | RSU | 625 | — | 3,739 |
| Richard Steinhart | RSU | 625 | — | 3,739 |
| Richard Steinhart | Option | 655 | 244.96 | — |
| Javier Rodriguez | Option | 659 | 244.96 | — |
| Vimal Mehta | RSU | 816 | — | 4,882 |
| Vimal Mehta | Option | 978 | 658.72 | — |
| Javier Rodriguez | Option | 1,132 | 313.6 | — |
| Richard Steinhart | Option | 1,132 | 313.6 | — |
| Javier Rodriguez | Option | 1,875 | 19.2 | — |
| Richard Steinhart | Option | 1,875 | 19.6 | — |
| Vimal Mehta | RSU | 1,969 | — | 11,779 |
| Vimal Mehta | Option | 3,268 | 244.96 | — |
| Javier Rodriguez | PSU | 4,375 | — | 26,173 |
| Richard Steinhart | PSU | 4,375 | — | 26,173 |
| Vimal Mehta | Option | 5,913 | 313.6 | — |
| Vimal Mehta | Option | 6,250 | 19.2 | — |
| Vimal Mehta | PSU | 15,625 | — | 93,475 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| David MackIndependent · Compensation Committee | $30,000 | $185,619 | $0 | — | — | $215,619 |
| Peter Mueller, Ph.DIndependent · Board Chair · Lead Independent Director · Audit Committee · Compensation Committee (Chair) · Nominating and Corporate Governance Committee (Chair) | 130,000 | 0 | 20,410 | — | — | 150,410 |
| Sandeep Laumas, M.DIndependent · Audit Committee (Chair) · Compensation Committee · Nominating and Corporate Governance Committee | 92,500 | 0 | 20,410 | — | — | 112,910 |
| Michael MillerIndependent · Audit Committee | 70,000 | 0 | 20,410 | — | — | 90,410 |
| Michal Votruba, M.DIndependent · Audit Committee | 70,000 | 0 | 20,410 | — | — | 90,410 |
| June BrayIndependent · Nominating and Corporate Governance Committee | 65,000 | 0 | 20,410 | — | — | 85,410 |
Board fee structure and ownership guideline
| Annual cash retainer | $60,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $457,500 |
| Equity awards (grant-date value) | $185,619 |
| All other compensation | $0 |
| Total cost of the board | $643,119 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names BioXcel Therapeutics as a peer
Companies that benchmark against BTAI
No companies currently name BTAI as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | BioXcel Therapeutics | 2024 | Vimal Mehta | $1,001,570 | $0 | $101,250 | $0 | $1,119,245 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-12-12 | 1,616,305 | 394,890 | 46,717 | 80.37% | Passed |
| 2024 | 2024-06-10 | 14,391,943 | 4,123,997 | 41,170 | 77.73% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-12-12 | 80.37%a |
| 2024 | 2024-06-10 | 77.73%b |
a. Approved under the standard stated in the filing — “Proposal No. 3 : Approval of Say-on-Pay -- The affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively on this proposal at the Annual Meeting by the holders entitled to vote thereon.”.
b. Approved under the standard stated in the filing — “The affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively at the Annual Meeting by the holders entitled to vote thereon.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Dividend-equivalent accruals | 2025-12-14 | — | 263 | — | — | 4 insiders, 4 accrual rows | ||
| Vimal Mehta | Director | 2025-12-14 | A | 164 | — | — | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2025-12-14 | A | 33 | — | — | Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2025-12-14 | A | 33 | — | — | Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2025-12-14 | A | 33 | — | — | Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2025-12-15 | A | 35 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-12-15 | — | 324 | — | — | 4 insiders, 4 accrual rows | ||
| Vimal Mehta | Director | 2025-12-15 | A | 219 | — | — | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2025-12-15 | A | 35 | — | — | Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2025-12-15 | A | 35 | — | — | Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-01-01 | A | 199,032 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2026-01-01 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2026-01-01 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-01-01 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Mack | Director | 2026-01-09 | A | 17,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| June Bray | Director | 2026-01-09 | A | 17,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Miller | Director | 2026-01-09 | A | 17,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michal Votruba | Director | 2026-01-09 | A | 17,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Mueller | Director | 2026-01-09 | A | 17,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rajiv Patni | Director | 2026-01-09 | A | 17,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandeep Laumas | Director | 2026-01-09 | A | 17,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-03-14 | — | 263 | — | — | 4 insiders, 4 accrual rows | ||
| Javier Rodriguez | See Remarks | 2026-03-14 | A | 33 | — | — | Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-03-14 | A | 164 | — | — | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2026-03-14 | A | 33 | — | — | Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-03-14 | A | 33 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-03-15 | — | 324 | — | — | 4 insiders, 4 accrual rows | ||
| Javier Rodriguez | See Remarks | 2026-03-15 | A | 35 | — | — | Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-03-15 | A | 219 | — | — | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2026-03-15 | A | 35 | — | — | Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-03-15 | A | 35 | — | — | Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2026-05-01 | D | 9,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-05-01 | A | 18,000 | — | — | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2026-05-01 | D | 9,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-05-01 | D | 9,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-05-01 | A | 9,000 | — | — | Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2026-05-01 | A | 9,000 | — | — | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2026-05-01 | A | 9,000 | — | — | Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-05-01 | D | 18,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-05-04 | D | 49,758 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-05-04 | A | 49,758 | — | — | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2026-05-04 | A | 17,500 | — | — | Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2026-05-04 | A | 17,500 | — | — | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2026-05-04 | D | 17,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2026-05-04 | D | 17,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-05-04 | D | 17,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-05-04 | A | 17,500 | — | — | Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2026-05-20 | D | 6,560 | 1 | 7,111 | Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-05-20 | D | 19,419 | 1 | 21,108 | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2026-05-20 | D | 6,845 | 1 | 7,427 | Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-05-20 | D | 6,845 | 1 | 7,427 | Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-06-15 | A | 219 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-15 | — | 324 | — | — | 4 insiders, 4 accrual rows | ||
| Richard Steinhart | Chief Financial Officer | 2026-06-15 | A | 35 | — | — | Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2026-06-15 | A | 35 | — | — | Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-06-15 | A | 35 | — | — | Common | Form 4 ↗ |
| Susan E. Atkins | Director | 2026-08-12 | A | 17,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 72 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Vimal Mehta | Director | 2025-12-14 | D | 164 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Vimal Mehta | Director | 2025-12-14 | A | 164 | — | — | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2025-12-14 | A | 33 | — | — | Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2025-12-14 | D | 33 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2025-12-14 | A | 33 | — | — | Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2025-12-14 | D | 33 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2025-12-14 | A | 33 | — | — | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2025-12-14 | D | 33 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2025-12-15 | A | 35 | — | — | Common | Form 4 ↗ |
| Vimal Mehta | Director | 2025-12-15 | D | 219 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vimal Mehta | Director | 2025-12-15 | A | 219 | — | — | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2025-12-15 | D | 35 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2025-12-15 | A | 35 | — | — | Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2025-12-15 | D | 35 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2025-12-15 | A | 35 | — | — | Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2025-12-15 | D | 35 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-01-01 | A | 199,032 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2026-01-01 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2026-01-01 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-01-01 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Mack | Director | 2026-01-09 | A | 17,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| June Bray | Director | 2026-01-09 | A | 17,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Miller | Director | 2026-01-09 | A | 17,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michal Votruba | Director | 2026-01-09 | A | 17,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Mueller | Director | 2026-01-09 | A | 17,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rajiv Patni | Director | 2026-01-09 | A | 17,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandeep Laumas | Director | 2026-01-09 | A | 17,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2026-03-14 | D | 33 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2026-03-14 | A | 33 | — | — | Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-03-14 | D | 164 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-03-14 | A | 164 | — | — | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2026-03-14 | A | 33 | — | — | Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-03-14 | D | 33 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-03-14 | A | 33 | — | — | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2026-03-14 | D | 33 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2026-03-15 | D | 35 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2026-03-15 | A | 35 | — | — | Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-03-15 | A | 219 | — | — | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2026-03-15 | A | 35 | — | — | Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-03-15 | D | 35 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-03-15 | A | 35 | — | — | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2026-03-15 | D | 35 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-03-15 | D | 219 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2026-05-01 | D | 9,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-05-01 | A | 18,000 | — | — | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2026-05-01 | D | 9,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-05-01 | D | 9,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-05-01 | A | 9,000 | — | — | Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2026-05-01 | A | 9,000 | — | — | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2026-05-01 | A | 9,000 | — | — | Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-05-01 | D | 18,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-05-04 | D | 49,758 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-05-04 | A | 49,758 | — | — | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2026-05-04 | A | 17,500 | — | — | Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2026-05-04 | A | 17,500 | — | — | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2026-05-04 | D | 17,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2026-05-04 | D | 17,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-05-04 | D | 17,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-05-04 | A | 17,500 | — | — | Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2026-05-20 | D | 6,560 | 1 | 7,111 | Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-05-20 | D | 19,419 | 1 | 21,108 | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2026-05-20 | D | 6,845 | 1 | 7,427 | Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-05-20 | D | 6,845 | 1 | 7,427 | Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-06-15 | A | 219 | — | — | Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2026-06-15 | D | 35 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Steinhart | Chief Financial Officer | 2026-06-15 | A | 35 | — | — | Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2026-06-15 | D | 35 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Javier Rodriguez | See Remarks | 2026-06-15 | A | 35 | — | — | Common | Form 4 ↗ |
| Vimal Mehta | Director | 2026-06-15 | D | 219 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-06-15 | D | 35 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Yocca | Chief Scientific Officer | 2026-06-15 | A | 35 | — | — | Common | Form 4 ↗ |
| Susan E. Atkins | Director | 2026-08-12 | A | 17,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Sources (95 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Vimal Mehta. DEF 14A, filed 2025-11-12. Section “Summary Compensation Table” · page 31. As printed: 1,119,245. View filing ↗
- Section 01, Javier Rodriguez. DEF 14A, filed 2025-11-12. Section “Summary Compensation Table” · page 31. As printed: 1,012,552. View filing ↗
- Section 01, Richard Steinhart. DEF 14A, filed 2025-11-12. Section “Summary Compensation Table” · page 31. As printed: 998,216. View filing ↗
- Section 03, Vimal Mehta OPTION. DEF 14A, filed 2025-11-12. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Vimal Mehta PSU. DEF 14A, filed 2025-11-12. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Javier Rodriguez PSU. DEF 14A, filed 2025-11-12. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Javier Rodriguez RSU. DEF 14A, filed 2025-11-12. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Richard Steinhart PSU. DEF 14A, filed 2025-11-12. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Richard Steinhart OPTION. DEF 14A, filed 2025-11-12. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Richard Steinhart RSU. DEF 14A, filed 2025-11-12. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Javier Rodriguez OPTION. DEF 14A, filed 2025-11-12. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, David Mack. DEF 14A, filed 2025-11-12. Section “Director Compensation”. As printed: 215,619. View filing ↗
- Section 08, Peter Mueller, Ph.D. DEF 14A, filed 2025-11-12. Section “Director Compensation”. As printed: 150,410. View filing ↗
- Section 08, Sandeep Laumas, M.D. DEF 14A, filed 2025-11-12. Section “Director Compensation”. As printed: 112,910. View filing ↗
- Section 08, Michael Miller. DEF 14A, filed 2025-11-12. Section “Director Compensation”. As printed: 90,410. View filing ↗
- Section 08, Michal Votruba, M.D. DEF 14A, filed 2025-11-12. Section “Director Compensation”. As printed: 90,410. View filing ↗
- Section 08, June Bray. DEF 14A, filed 2025-11-12. Section “Director Compensation”. As printed: 85,410. View filing ↗
- Section 02, Vimal Mehta 2025-12-14. Form 4, filed 2025-12-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vimal Mehta 2025-12-14. Form 4, filed 2025-12-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Steinhart 2025-12-14. Form 4, filed 2025-12-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Yocca 2025-12-14. Form 4, filed 2025-12-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Yocca 2025-12-14. Form 4, filed 2025-12-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Javier Rodriguez 2025-12-14. Form 4, filed 2025-12-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Javier Rodriguez 2025-12-14. Form 4, filed 2025-12-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Steinhart 2025-12-14. Form 4, filed 2025-12-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Javier Rodriguez 2025-12-15. Form 4, filed 2025-12-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vimal Mehta 2025-12-15. Form 4, filed 2025-12-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vimal Mehta 2025-12-15. Form 4, filed 2025-12-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Steinhart 2025-12-15. Form 4, filed 2025-12-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Steinhart 2025-12-15. Form 4, filed 2025-12-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Yocca 2025-12-15. Form 4, filed 2025-12-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Yocca 2025-12-15. Form 4, filed 2025-12-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Javier Rodriguez 2025-12-15. Form 4, filed 2025-12-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vimal Mehta 2026-01-01. Form 4, filed 2026-01-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Steinhart 2026-01-01. Form 4, filed 2026-01-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Javier Rodriguez 2026-01-01. Form 4, filed 2026-01-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Yocca 2026-01-01. Form 4, filed 2026-01-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Mack 2026-01-09. Form 4, filed 2026-01-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, June Bray 2026-01-09. Form 4, filed 2026-01-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Miller 2026-01-09. Form 4, filed 2026-01-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michal Votruba 2026-01-09. Form 4, filed 2026-01-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Mueller 2026-01-09. Form 4, filed 2026-01-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rajiv Patni 2026-01-09. Form 4, filed 2026-01-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sandeep Laumas 2026-01-09. Form 4, filed 2026-01-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Javier Rodriguez 2026-03-14. Form 4, filed 2026-03-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Javier Rodriguez 2026-03-14. Form 4, filed 2026-03-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vimal Mehta 2026-03-14. Form 4, filed 2026-03-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vimal Mehta 2026-03-14. Form 4, filed 2026-03-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Steinhart 2026-03-14. Form 4, filed 2026-03-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Yocca 2026-03-14. Form 4, filed 2026-03-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Yocca 2026-03-14. Form 4, filed 2026-03-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Steinhart 2026-03-14. Form 4, filed 2026-03-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Javier Rodriguez 2026-03-15. Form 4, filed 2026-03-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Javier Rodriguez 2026-03-15. Form 4, filed 2026-03-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vimal Mehta 2026-03-15. Form 4, filed 2026-03-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Steinhart 2026-03-15. Form 4, filed 2026-03-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Yocca 2026-03-15. Form 4, filed 2026-03-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Yocca 2026-03-15. Form 4, filed 2026-03-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Steinhart 2026-03-15. Form 4, filed 2026-03-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vimal Mehta 2026-03-15. Form 4, filed 2026-03-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Javier Rodriguez 2026-05-01. Form 4, filed 2026-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vimal Mehta 2026-05-01. Form 4, filed 2026-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Steinhart 2026-05-01. Form 4, filed 2026-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Yocca 2026-05-01. Form 4, filed 2026-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Yocca 2026-05-01. Form 4, filed 2026-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Javier Rodriguez 2026-05-01. Form 4, filed 2026-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Steinhart 2026-05-01. Form 4, filed 2026-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vimal Mehta 2026-05-01. Form 4, filed 2026-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vimal Mehta 2026-05-04. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vimal Mehta 2026-05-04. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Steinhart 2026-05-04. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Javier Rodriguez 2026-05-04. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Steinhart 2026-05-04. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Javier Rodriguez 2026-05-04. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Yocca 2026-05-04. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Yocca 2026-05-04. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Javier Rodriguez 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vimal Mehta 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Steinhart 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Yocca 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vimal Mehta 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Steinhart 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Steinhart 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Javier Rodriguez 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Javier Rodriguez 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vimal Mehta 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Yocca 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Yocca 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susan E. Atkins 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-12-15. Item 5.07 · say-on-pay result. As reported: 80.37% (votes for as printed: 1,616,305). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-12. Item 5.07 · say-on-pay result. As reported: 77.73% (votes for as printed: 14,391,943). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 457,500 + equity 185,619 + all other 0 = 643,119, summed across the director compensation table rows.
- BioXcel Therapeutics (subject), Section 10b CEO total. DEF 14A, filed 2025-11-12. CEO total compensation as printed in BioXcel Therapeutics's own proxy. As printed: 1,119,245. View filing ↗